Professional Media briefs

Fox P2 Media launched The Medical Roundtable, a peer-reviewed, subscriber-supported quarterly being distributed to over 5,000 US cardiologists. The first issue contains nine roundtable discussions spanning 68 pages and including 30 experts.

Wolters Kluwer made its Adis journal Drugs in R&D open access, with all content available online free of charge. The journal, for which access was formerly fee-based, features original research and reviews from all phases of clinical development.

Quadrant Healthcom named Toby Jane Hindin editor of The Female Patient. She joins the company from the health sciences division and the pharma/science division of Advanstar, where she was chief editor of Contemporary Pediatrics and editor in chief for Applied Clinical Trials. She reports to Margo Ullman, publisher.

Advanstar told Folio Magazine it will outsource production, resulting in the elimination of 100 jobs at its Duluth, MN location. With titles covering fashion and powersports as well as life sciences, the trade publisher is struggling to eliminate debt following its acquisition by private equity firm Veronis Suhler Stevenson in 2007.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.